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Introduction
Interferon gamma (IFN␥) is the principal macrophage activating factor and a key inflammatory mediator in some systemic and organ-specific autoimmune diseases. [1] [2] [3] NOD mice spontaneously develop autoimmune insulindependent diabetes mellitus (IDDM). 4, 5 Islets of Langerhans are infiltrated by T cells, macrophages and other lymphoid cells (insulitis), and beta islet cells are selectively destroyed. In these mice, IFN␥ is detectable in inflamed islets of Langerhans, and appears to play a role in pathogenesis since administration of either anti-IFN␥ mAb 6, 7 or soluble IFN␥ receptors (IFN␥R) protects from disease. 7 The administration of IL-12 to these mice promotes a T-helper type 1 (Th1) response to islet cell antigens with increased IFN␥ production and rapidly induces diabetes. Similarly, the administration of cyclophosphamide (CYP) to NOD mice augments intra-islet IFN␥ production 8, 9 and provokes early onset of insulitis and diabetes. [8] [9] [10] On the other hand, we have recently shown that gene therapy with plasmid vectors expressing either transforming growth factor beta-1 (TGF-␤1), 9 or an IL-4/IgG1 fusion protein (manuscript in preparation) protect NOD mice from disease. These cytokines have immunosuppressive or immunoregulatory effects. Based on the work of Wolff and coworkers, 11 we opted for i.m. injection of
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Received 11 September 1998; accepted 7 December 1998 naked plasmid vectors. Our results, and those of others, 9, 12, 13 point to cytokine gene therapy as being an effective method of preventing autoimmunity. However, in humans this approach may be limited due to the toxicity of various cytokines, as noted in clinical trials. 14 Clearly, the ideal form of immunotherapy should be nontoxic, as well as long-lasting to avoid frequent reinjections of the vector. Moreover, the vector and the therapeutic protein should both be non-immunogenic, so that the treatment can be reapplied several times, as required, without eliciting a neutralizing immune response. In this study, we demonstrate that all these conditions can be met with a plasmid vector expressing a soluble cytokine receptor.
We constructed a vector encoding a fusion protein consisting of the extracellular portion of the murine high affinity IFN␥ receptor alpha chain (IFN␥R) joined to mouse IgG1 heavy chain constant regions, and secreted as a homodimer (henceforth referred to as IFN␥R/IgG1). This was done by inserting the appropriate cDNA segments into the VICAL VR-1255 plasmid, 15 where transcription is dependent on a CMV immediate-early enhancer-promoter. The fusion protein effectively blocks IFN␥ activity in vitro. We report that i.m. injection of this vector in mice results in substantial production of the soluble receptor. After injections of 200-400 g of DNA we observed serum levels exceeding 100 ng/ml for months. These serum levels are sufficient to neutralize IFN␥ in vivo, and to protect mice from autoimmune diabetes in two different experimental models.
Results
Construction of the IFN␥R/IgG1-encoding vector (VR-1255-IFN␥R/IgG1) The features of the VICAL VR-1255 eukaryotic expression vector have been reported by Hartikka et al. 15 The vector has a CMV immediate-early enhancer-promoter, CMV intron A, a single eukaryotic transcription unit, and minimal rabbit beta globin polyadenylation and transcriptional termination sequences. PCR generated cDNA segments of IFN␥R (extracellular portion, with N terminal signal peptide) and IgG1 constant regions (part of CH1, hinge, CH2 And CH3) were joined and inserted into the vector as described in Materials and methods. A map is shown in Figure 1a .
The supernatants of COS-7 cells transfected with this Figure 1b .
IFN␥R/IgG1 neutralizes IFN␥ in vitro
The ability of the IFN␥R/IgG1 fusion protein to block IFN␥ activity was determined in a macrophage activation assay, which depends on IFN␥-enhanced nitric oxide (NO) production. When a macrophage cell line is cultured overnight with IFN␥ in the presence of lipopolysaccharide (LPS), NO release is proportional to the concentration of IFN␥. In culture, NO is rapidly transformed to NO 2 − , which is detected by a colorimetric test. 16 IFN␥R/IgG1 fusion protein effectively inhibited IFN␥, and was more strongly inhibitory than a commonly used neutralizing anti-IFN␥ mAb (R4-6A2), 6, 17 under identical conditions ( Figure 2 ). In this assay, 50% inhibition of the activity of 200 pg/ml of IFN␥ required a 12-fold excess of soluble receptor by weight (or 3.5-fold on a molar basis), compared with a 110-fold excess for the mAb (by weight).
I.m. injection of naked IFN␥R/IgG1 vector results in prolonged production of IFN␥R/IgG1 fusion protein Male CD-1 mice were injected with 100 g of naked VR-1255-IFN␥R/IgG1 plasmid vector or control blank vector in one rectus femoris and one tibialis anterior muscle (200 g of DNA per treatment) on two occasions. Injection of VR-1255-IFN␥R/IgG1 resulted in detectable serum levels of IFN␥R/IgG1 fusion protein, as determined with an ELISA assay specific for this protein ( Figure 3) . Notably, serum levels persisted at above 100 ng/ml for over 3 months after the last DNA injection. As expected, the fusion protein was undetectable in control vector-treated mice. Similarly elevated serum levels of IFN␥R/IgG1 were found in NOD mice (not shown). IFN␥R/IgG1 blocks IFN␥-induced macrophage activation in vivo Previous studies have shown that administration of CYP in NOD mice accelerates disease and increases IFN␥ production locally in the islets of Langerhans; however, to our knowledge the serum levels of IFN␥ in these mice have not been previously reported. In preliminary experiments, we found that CYP treatment (200 mg/kg) results in IFN␥ serum levels of Ͼ70 pg/ml 15 days after drug administration. In addition, our results suggest that induced IFN␥ production results in the priming of peritoneal macrophages, since these cells produce increased amounts of NO when stimulated in vitro with LPS ( Figure 4 ).
The administration of VR-1255-IFN␥R/IgG1 vector, but not control blank vector, inhibited macrophage activation in CYP-treated NOD mice ( Figure 4) .
A similar inhibition was observed in another model of drug-induced IFN␥ production. As demonstrated by Cockfield et al, 18 administration of STZ to normal (nonautoimmune mice) results in systemic release of IFN␥, associated with effects that can be blocked in vivo with the R4-6A2 neutralizing anti-IFN␥ mAb. In accordance with their findings, we found that the peritoneal macrophages of STZ-treated mice are activated, ie produce more NO when stimulated with LPS, and this effect is blocked by administration or R4-6A2 (data not shown).
As in CYP-treated NOD mice, VR-1255-IFN␥R/IgG1 administration blocked macrophage activation in STZtreated CD-1 mice (Figure 4 ), consistent with in vivo inhibition of IFN␥ by the encoded soluble IFN␥ receptor.
These results suggest, in both disease models, that sufficient interferon inhibitor is produced in vector-treated mice to block IFN␥-mediated effects.
VR-1255-IFN␥R/IgG1 administration prevents insulitis and diabetes
Previous studies have demonstrated that IFN␥ inhibitors can prevent CYP-accelerated NOD-mouse diabetes, and multiple low-dose STZ-induced diabetes (MDSD model) in other strains. In these two disease models, we find that administration of VR-1255-IFN␥R/IgG1 considerably 
produced by the cells of VR-1255-IFN␥R/IgG1-treated NOD mice were below the detection limit of the assay (Ͻ1). Also, levels of NO 2 − produced by the cells of control NOD and CD-1 mice treated with either no vector (saline only), blank vector or VR-1255-IFN␥R/IgG1, but not treated with either CYP or STZ, were below the detection limit of the assay (Ͻ1) (not shown). The difference between experimental and control mice was significant (P Ͻ 0.01). (ᮀ), CYP-treated female NOD mice; (a), STZtreated male CD-1 mice.
protects from insulitis, which is the precursor lesion leading to diabetes (P Ͻ 0.001 in both disease models) ( Table 1) .
In CD-1 mice treated with multiple low doses of STZ, 4% of mice in the experimental group developed diabetes, compared with 48% in the control group (P Ͻ 0.0004) at day 50 (Table 1) . In another experiment, at week 14 the incidence of diabetes was five of 10 in the blank vector-treated group, and none of 10 in the VR-1255-IFN␥R/IgG1-treated group (P Ͻ 0.02) (data not shown). Thus, the therapeutic effect was long-lasting. Therapy was equally effective at protecting C57BL/6 mice from MDSD (data not shown).
In CYP-treated NOD mice, the incidence of diabetes was 10% in the experimental group and 89% in the control group (P Ͻ 0.001) ( Table 1) . Thus, gene therapy was highly effective at preventing induced diabetes in these mice. 
Discussion
Numerous studies suggest that IFN␥ is a key inflammatory cytokine in IDDM, SLE and many other autoimmune and/or inflammatory disorders. [1] [2] [3] [4] [5] [6] [7] [8] [9] 19, 20 IFN␥ neutralizing mAbs or soluble receptors are frequently protective in these disorders. Conversely, transgenic mice expressing IFN␥ in the islets of Langerhans develop severe insulitis and diabetes. 21 This is associated with a loss of immunologic tolerance to islet-cell antigens. Similarly, we found that administration of IFN␥ to NOD mice by a somatic gene therapy approach is detrimental. 9 In NOD mice, Wang et al 22 report that IFN␥ acts at several points in the progression of autoimmune diabetes. Mutant mice lacking functional IFN␥ receptors have much less severe insulitis and do not develop diabetes. 22 Inhibition of IFN␥ is protective in both CYP-accelerated NOD-mouse diabetes and MDSD. 6, 7, 18, 23 The mode of action of IFN␥ in these animal models of IDDM is not fully elucidated. In vitro, this cytokine is toxic to islet cells, particularly in combination with IL-1 and TNF␣. 19, 24, 25 Thus, it could act directly on islet beta cells; however, it could also exert its effects by activating macrophages. 26 In fact, there is considerable evidence that activated macrophages release mediators toxic to islet cells, including NO and other oxygen radicals, [26] [27] [28] [29] and probably other mediators as well. In accordance with this view, depletion of macrophages protects NOD mice. 30 In addition, IFN␥ may play an important role in stimulating islet-cell antigen presentation by the APC, and/or in inducing Th1 differentiation of autoreactive T cells. 31 Clinically, the neutralization of IFN␥ could be beneficial in many inflammatory diseases. Although IFN␥ can be neutralized by mAb or soluble IFN␥ receptor, this approach has limitations since relatively large amounts of proteins must be administered frequently. 7 The serum levels of the neutralizing protein are likely to vary widely during the course of therapy. Moreover, mAb from other species are frequently neutralized by antibodies. It is apparent that there would be great advantage in delivering a nonimmunogenic IFN␥ inhibitor by a gene therapy method. An appropriate therapy should be nontoxic, and provide sufficient and constant delivery of the inhibitor over periods of weeks to months, with minimal intervention by the patient or physician. Additionally, at least for the treatment of chronic diseases, it should be possible to readminister the vector many times. This will be difficult unless the vector itself is non-immunogenic.
We have addressed these questions by designing a nonviral vector that encodes a secreted IFN␥ inhibitory fusion protein, incorporating the extracellular segment of the IFN␥R alpha chain. We cloned the relevant cDNA segments into the plasmid vector VICAL VR-1255. This vector has a CMV immediate-early enhancer-promoter, CMV intron A, and minimal rabbit beta globin polyadenylation and transcriptional termination sequences. 15 It is particularly effective when administered i.m. as naked DNA. 15 There are advantages to using fusion proteins with immunoglobulin Fc segments as inhibitors, instead of truncated soluble cytokine receptors. These fusion proteins (often called immunoadhesins) are usually secreted as homodimers. 23, [31] [32] [33] The Fc portion simplifies purification of the protein by affinity chromatography. 33 More importantly, previous studies have shown that IFN␥R/Fc fusion proteins have a much longer half-life in body fluids than truncated IFN␥R, 23 possibly because the larger size of immunoadhesins prevents rapid clearance in the kidney. 34 Also, dimeric IFN␥R/Fc fusion proteins can usually bind IFN␥ with greater avidity than single chain receptors, presumably because this cytokine is a homodimer. 33 For insertion into the vector, we chose heavy chain elements (part of CH1, hinge, CH2 and CH3) of the murine IgG1 isotype, instead of other isotypes, because IgG1 has a long half-life in serum and does not activate complement. Although it is unclear if other immunoadhesins reported in the literature can activate complement, our construct eliminates this possibility. The activation of complement would be particularly undesirable due to release of several inflammatory mediators, possibly negating the effects of therapy.
Following transient transfection of COS-7 cells with VR-1255-IFN␥R/IgG1, the fusion protein was secreted as a disulfide-linked homodimer with an apparent molecular weight of 130 kDa. This structure is similar to receptor/IgG constructs reported by others. 23, [31] [32] [33] [34] This secreted protein inhibits IFN␥ in an in vitro assay of macrophage activation, and is more effective than the commonly used R4-6A2 IFN␥-neutralizing mAb.
To analyze the efficacy of VR-1255-IFN␥R/IgG1 vector as a therapeutic agent, we injected it i.m. as naked DNA, at a total dose of 200-400 g (100 g per muscle). The IFN␥R/IgG1 fusion protein was secreted and easily detectable in serum. In most mice receiving 400 g of DNA, serum levels remained in the range of 100-200 ng/ml for periods of over 3 months. This was sufficient to neutralize IFN␥ in two models of autoimmune diabetes characterized by systemic release of this cytokine, ie CYP-treated NOD mice, and multiple low-dose STZ-treated CD-1 or C57BL/6 mice. In both disease models, therapy was associated with a decrease in the severity of insulitis, as well as a markedly reduced incidence of diabetes.
In these mice, systemic release of IFN␥ (detectable in serum by ELISA) was associated with priming of peritoneal macrophages, as occurs when these cells are incubated with IFN␥ in vitro. Thus, recovered peritoneal macrophages of control CYP-or STZ-treated mice produced markedly increased amounts of NO when incubated with LPS. We found that i.m. gene transfer of VR-1255-IFN␥R/IgG1 blocked this macrophage activation, as did injection of a neutralizing anti-IFN␥ mAb. Thus, we conclude that gene therapy successfully neutralized IFN␥ in these disease conditions.
Our IFN␥R/IgG1 immunoadhesin is constituted of segments of endogenous murine proteins, which are not expected to be immunogenic. Consistent with this, we found no evidence that treated mice develop antibodies against this fusion protein. Antibodies failed to develop despite the systemic presence of the protein for periods of several weeks. We have not been able to induce such antibodies in mice that were treated with vector DNA for up to five times over a period of 3 months (our unpublished observation). Thus, there is no evidence that these repeated injections can break immunologic tolerance to the fusion protein.
The serum levels of protein attained in the current study are much greater (one to three orders of magnitude) than we observed previously in mice injected i.m. with either a TGF-␤1-encoding plasmid vector, 9 or similar vectors encoding other cytokines (IL-4, IL-12, and IFN␥; unpublished observations). There are a number of possible reasons for this. We had cloned TGF-␤1 and other cytokines into pCI-Neo, 9 a vector that is expressed at a much lower level than VR-1255 following i.m. delivery (unpublished observation). Moreover, the half-lives of these cytokines in serum is short compared with immunoadhesins.
Another major difference to our previous results is the persistence of expression. With pCI-Neo, a vector that encodes neomycin phosphotransferase (a protein that is immunogenic in mice), we have observed that following i.m. gene transfer cytokine production declines rapidly after 2 weeks. We (C Piccirillo and GJ Prud'homme, manuscript in preparation) and others, 35 found that this rapid decline is due to immune responses to immunogenic vector-encoded proteins (in our case neomycin phosphotransferase). This decline is not observed in mice with severe combined immunodeficiency (SCID). On the other hand, VR-1255 has only one eukaryotic transcription unit (the cloning site), ie it does not encode an immunogenic protein unless such a sequence is deliberately inserted. Therefore, we postulate that the prolonged expression of VR-1255-IFN␥R/IgG1 after i.m. injection is attributable to the non-immunogenic nature of the encoded protein.
The delivery of IFN␥ inhibitory molecules by i.m. injection of plasmid vectors is simple and appears to be nontoxic and safe. A limitation of our approach is that the inhibitor will inhibit all IFN␥-dependent responses. In the future, it would be desirable to develop a technique where the inhibitor is produced in situ and does not interfere with other immune responses.
The use of this technology circumvents some of the problems encountered with viral vectors. Unlike viruses, the plasmid has no potential for reactivation to a pathogenic state and is not likely to be incorporated into genomic DNA. In addition, our vector is not neutralized by the host's immune response and does not stimulate an inflammatory response at the site of injection (our unpublished observation). The use of cytokine receptors instead of cytokines for immunotherapy has the additional advantage of low or absent toxicity. This is particularly important when long-term therapy is required. Finally, inhibition of IFN␥ is protective in a large number of autoimmune or inflammatory conditions as well as in allograft rejection.
Materials and methods

Mice
Female NOD mice (8-10 weeks old) were purchased from Taconic Farms (Germantown, NY, USA). Male CD-1 mice (8-10 weeks old) were purchased from Charles River Canada (St Constant, Quebec, Canada). Mice were housed under pathogen-free conditions.
Construction of IFN␥R/IgG1 expression vector
Mouse IFN␥R alpha chain cDNA was prepared by RT-PCR, from RNA of LPS-stimulated mouse splenic cells, and amplified with this pair of primers: 5′-TAG TAG GAT ATC CTG TCA GAG GTG TCC CTC GCG CAG GAA (sense) and 5′-AAC GTT GCA GGT GAC GGT CTC GCT AGG AGG GAT ACA GAC GTC TTT CGA T (antisense). Mouse IgG1 constant heavy chain cDNA was produced by RT-PCR, from RNA extracted from an IgG1-secreting hybridoma, and amplified with this pair of primers: 5′-ATC GAA AGA CGT CTG TAT CCC TCC TAG CGA GAC CGT CAC CTG CAA CGT T (sense) and 5′-TAT TAT GAA TTC GAG GTA GGT GTC AGA GTC CTG TAG G (antisense). RNA extraction, reverse transcription and PCR amplification were performed as previously described. 20 In all cases, PCR amplification was performed with Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). These PCR-generated cDNA fragments were designed for overlap. The IFN␥R/IgG1 encoding sequence was generated by PCR amplification of the overlapping DNA segments, as we have described 20 (see Figure 1a) . This segment was then inserted into EcoRV and EcoRI restriction sites of the VICAL VR-1255 vector, 15 after deletion of the original luciferase cDNA segment.
Plasmid DNA preparation Plasmid DNA was prepared by the alkaline lysis method using the Qiagen Mega Prep kit (Qiagen, Santa Clarina, CA, USA), according to the manufacturer's instructions. The purity of DNA preparations was confirmed on 1% agarose gel. DNA prepared for i.m. injections was dissolved in 0.85% saline and stored at −20°C.
Transfection of COS-7 cells
COS-7 cells were transfected with VR1255-IFN␥R/IgG1 plasmid DNA using a standard DNA-calcium phosphate coprecipitation technique. Cells were maintained in DMEM with 5% FBS at 37°C in 5% CO 2 . Supernatants were collected at 72 h and stored at Ͻ−80°C. The production of secreted IFN␥R/IgG1 fusion protein was confirmed by detection in supernatants with a specific ELISA (see below). Biological activity was demonstrated by neutralizing IFN␥-stimulated NO production in RAW 264.7 cell lines (assay described below).
ELISA assays
ELISA detecting IFN␥R/IgG1 fusion protein, but not native IFN␥R which lacks IgG1 determinants, was performed as follows: 96-well plates (Nunc-Immuno, Canadian Life Technologies, Burlington, Ontario, Canada) were coated overnight with purified anti-IFN␥R mAb (clone GR-20; obtained from ATCC, Rockville, MD, USA) in carbonate buffer, pH 9.6, at 4°C. After washing with PBST the wells of the plate were blocked with 3% BSA for 1 h at 37°C. As a second layer, culture supernatants or sera were applied to the plate for 1.5 h at 37°C. After additional washings, a third layer consisting of rat biotinylated anti-mouse IgG1 (PharMingen Canada, Mississauga, Ontario, Canada) was applied to the plate. This was followed by washing and incubation with alkaline phosphatase-streptavidin conjugate (Bio-Rad Laboratories, Hercules, CA, USA). The reaction was developed and read by a standard method.
To detect serum antibodies reactive to the IFN␥R/IgG1 fusion protein, the ELISA assay was modified as follows. Again, plates were coated with GR-20 mAb, a second layer of IFN␥R/IgG1 protein was added, followed by a third layer of mouse serum (the potential source of fusion protein-binding antibodies). The fourth layer consisted of alkaline phosphatase-conjugated rat anti-mouse kappa light chain antibody (Zymed Laboratories, Markham, Ontario, Canada). This antibody does not react to the fusion protein or to GR-20 (a rat mAb), but will detect mouse immunoglobulins that have a kappa light chain (95% of all immunoglobulins in the mouse).
SDS-PAGE and Western blotting IFN␥R/IgG1 fusion was visualized as follows: fractionation by SDS-PAGE electrophoresis and transfer to Immun-Blot PVDF membranes (Bio-Rad Laboratories) as described. 36 Membrane containing transferred proteins was blocked with PBST-3% BSA for 1 h at room temperature, then incubated with alkaline phosphataseconjugated goat anti-mouse IgG-Fc antibodies (Sigma Chemical, St Louis, MO, USA) at 1:2000 dilution for 2 h at room temperature and visualized.
Mouse serum samples of treated mice were shown to lack antibodies reactive to the fusion protein as follows. The IFN␥R/IgG1 fusion protein was separated by SDS-PAGE and transferred to Immun-Blot PVDF membranes as described above. Serum from mice was applied to the membrane, followed by alkaline phosphate-conjugated anti-mouse kappa light chain antibody (same antibody as for the ELISA assay).
IFN␥ assay and neutralization in vitro
The RAW264.7 cell line (ATCC, TIB 71) was used for NO 2 − production and neutralization. Briefly, RAW264.7 cells were grown in 96-well plates in DMEM (GIBCO BRL, Grand Island, NY, USA) containing 10% FBS at a density of 20 000 cells/200 l per well, at 37°C in 5% CO 2 for 20 h. The supernatant was discarded and 100 l of medium containing mouse IFN␥, with or without dilutions of either IFN␥R/IgG1 or R4-6A2 mAb, were added to the well, along with 100 l of DMEM with 5% FBS and 20 ng of LPS (E. coli 026:B6, Sigma Chemical). After a further 24 h culture, supernatant was collected and NO 2 − was measured using Griess reagents as described. 16 Absorbance was measured at 540 nm in a microplate reader (Titertek Instruments, Hunstville, AL, USA). Inhibition of interferon activity was calculated as follows: Inhibition of IFN␥ activity in vivo Following i.m. DNA-plasmid injections, peritoneal mononuclear cells of NOD or CD-1 mice were collected by peritoneal washing, as we have previously described. 37 The cells were grown in 96-well plates at a density of 150 000 cells per well in 200 l RPMI-1640 (GIBCO), with 5% FBS and 10 ng LPS for 24 h. Supernatants were collected for NO 2 − measurement as described above. Statistical analysis was performed with the Student's t test.
Intramuscular injection of plasmid DNA Intramuscular injections of plasmid DNA were performed as we have previously described. 9 Briefly, the rectus femoris or tibialis anterior muscles of anesthetized NOD or CD-1 mice (8-10 weeks old) were injected with 100 g of plasmid DNA in a volume of 50 l of saline, using a disposable sterile plastic insulin syringe and 29G1/2 needle fitted with a plastic collar to limit needle penetration to 2 mm. Unless stated otherwise, each mouse received a total 200 g of plasmid DNA per treatment session.
Induction of diabetes with STZ or CYP Male CD-1 mice were injected i.p. daily for 5 days with STZ (ICN, Aurora, OH, USA), at a dose of 30 mg/kg in 0.85% saline. Female NOD mice were injected i.p. with CYP (Sigma Chemical) at a dose of 200 mg/kg in 0.85% saline. Blood glucose levels were monitored using Chemstrip bG strips and an Accu-checkIII monitor (Boehringer Mannheim Biochemicals, Montreal, Canada). A diagnosis of diabetes was made when blood glucose levels equaled or exceeded 300 mg/dl. We did not observe reversal of hyperglycemia in mice with such high levels of blood glucose (our unpublished observations). Statistical analysis of diabetes incidence was performed with Fisher's exact test.
Histology
Pancreas was fixed in 10% buffered formalin and stained by hematoxylin and eosin. Grading of islet lesions was performed as described by Herold et al: 38 grade 0 = no intra-islet cellular infiltrates (infiltrates limited to the peri-islet area were also scored as 0); grade 1 = intra-islet mononuclear cell infiltration, but preservation of islet architecture; and grade 2 = numerous intra-islet inflammatory cells often with a loss of normal islet architecture. The distribution of lesions was compared by the 2 test.
